Table 5.
Sample characteristics of the HGSOC patients.
| Sample ID | Age, Years | FIGO | CA 125 Level before Treatment, U/mL | Risk of Malignancy Index (RMI) | Neoadjuvant Chemotherapy | Tumor Length, cm * | Tumor Width, cm * | Tumor Height, cm * | Ascites, mL | Extent of Blood Loss, mL | Surgery Time, min | 0—Complete Cytoreduction (Size of Residual Tumor Foci Less than 2.5 mm), 1—Suboptimal Cytoreduction (Size of Residual Tumor Foci 2.5 mm–2.5 cm) | Progesterone Receptor Expression in Tumor, Allred Score ** | Cluster Number in Figure 4 | RECIST 1.1 MRI/CT Criteria: 1—Complete Response, 2—Partial Response, 3—Stable Disease, 4—Progressive Disease |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1008 | 38 | IVB | 1244 | 10,359 | No | 7 | 10.5 | 11 | 2000 | 700 | 480 | 1 | 0 | 1 | 3 |
| 766 | 54 | IIB | 29 | 261 | No | 4 | 3 | 3 | 20 | 150 | 140 | 0 | 0 | 1 | 1 |
| 690 | 48 | IVB | 1340 | 12,060 | No | 5.5 | 3.5 | 4 | 50 | 700 | 206 | 0 | 0 | 1 | 3 |
| 679 | 51 | IIIC | 2000 | 18,000 | No | 9.5 | 6 | 8 | 1000 | 750 | 235 | 0 | 0 | 1 | 3 |
| 649 | 54 | IIIC | 200 | 1800 | Yes | 5 | 6 | 7 | 3000 | 650 | 285 | 1 | 0 | 1 | 4 |
| 15 | 57 | IIC | 198 | 1782 | No | 18 | 14 | 10 | 1000 | 400 | 190 | 1 | 0 | 1 | 4 |
| 19 | 63 | IIIC | 41 | 1206 | No | 6 | 2.4 | 4.6 | 200 | 400 | 265 | 1 | 0 | 1 | 1 |
| 782 | 45 | IIB | 517 | 1551 | No | 16 | 16 | 11.7 | 50 | 500 | 215 | 0 | 2 | 1 | 3 |
| 10 | 44 | IIIB | 129 | 387 | No | 6 | 7 | 6 | 700 | 500 | 175 | 1 | 5 | 1 | 1 |
| 13 | 71 | IIIB | 517 | 1551 | yes | 13 | 10 | 8 | 10 | 250 | 165 | 1 | 0 | 1 | 4 |
| 12 | 45 | IIA | 60 | 180 | No | 4 | 3 | 2 | 10 | 100 | 80 | 0 | 0 | 1 | 3 |
| 16 | 44 | IIIC | 92 | 277 | No | 5 | 4 | 4 | 10 | 300 | 185 | 1 | 0 | 1 | 3 |
| 17 | 47 | IA | 60 | 60 | No | 8.3 | 7.1 | 6.6 | 10 | 150 | 151 | 1 | 0 | 1 | 3 |
| 1060 | 77 | IIIC | 1203 | 10,827 | No | 10 | 9 | 8 | 1200 | 650 | 365 | 0 | 4 | 2 | 1 |
| 939 | 33 | IIIC | 59 | 270 | No | 13 | 12 | 10 | 2000 | 800 | 205 | 1 | 6 | 2 | 1 |
| 672 | 41 | IIIC | 1088 | 3264 | No | 9 | 7.5 | 10 | 1500 | 800 | 275 | 0 | 3 | 2 | 1 |
| 684 | 42 | IIIC | 1293 | 3879 | No | 14 | 8 | 6 | 1500 | 500 | 280 | 0 | 3 | 2 | 1 |
| 448 | 51 | IVB | 3808 | 11,424 | No | 15 | 17 | 18 | 10 | 3000 | 360 | 0 | 0 | 2 | 1 |
| 1061 | 49 | IIIC | 1756 | 5540 | No | 29.9 | 15 | 18.8 | 9000 | 3000 | 590 | 1 | 0 | 2 | 1 |
| 11 | 48 | IC | 189 | 567 | No | 18 | 10 | 8 | 10 | 300 | 375 | 0 | 6 | 2 | 4 |
* Intraoperative size. ** The Allred score combines the percentage of positive cells and the intensity of the reaction product in most of the carcinomas. Scores of 0–2 are considered negative. Scores of 3–8 are considered positive.